Optimism surrounds Alexion Pharmaceuticals, as it gets ready to report its third quarter results on Thursday, October 24, 2013. Analysts are expecting the company to book a profit of 71 cents a share, up from 53 cents a year ago.
The consensus estimate is up from three months ago when it was 70 cents, but hasn't changed over the past month. Analysts are expecting earnings of $2.71 per share for the fiscal year. Revenue is expected to be $395.3 million for the quarter, 34% higher than the year-earlier total of $294.1 million. For the year, revenue is expected to come in at $1.53 billion.
Over the last four quarters, the company has seen an average of 37% year-over-year growth in revenue. The biggest rise came in the third quarter, with revenue growing 44% from the year-ago quarter.
The majority of analysts (78%) rate Alexion Pharmaceuticals as a buy. This compares favorably to the analyst ratings of 10 similar companies, which average 60% buys.
Earnings estimates provided by Zacks.
Narrative Science, through its proprietary artificial intelligence platform, transforms data into stories and insights.
